BioNTech's ASCO Weekend: Two Cancer Data Sets Could Decide the Stock’s Next Move

BioNTech faces critical ASCO readouts on bispecific antibody and ADC assets, with €16.8B cash reserve funding late-stage trials as vaccine revenue fades.

BioNTech enters a defining week with its oncology pipeline under the microscope, while the financial scars of its Covid vaccine pivot deepen. The Mainz-based company reported a first-quarter net loss of nearly €532 million, as research spending surged to €557 million. Yet a cash fortress of €16.8 billion gives management the runway to fund more than 25 late-stage clinical trials. The ASCO cancer conference in Chicago, starting Friday, will test whether those billions are well spent.

The weekend will deliver a double dose of clinical clarity. On Saturday, the company presents new results for two priority assets. Pumitamig, a bispecific antibody, is being evaluated in a phase 2/3 interim analysis for lung cancer, where early signs show encouraging anti-tumor activity when combined with chemotherapy — with prior positive signals in small-cell lung cancer and breast cancer. Separately, Gotistobart targets platinum-resistant ovarian cancer, with phase 2 data suggesting durable responses and a manageable safety profile.

Alongside these spotlighted drugs, BioNTech will display four poster presentations covering antibody-drug conjugates (ADCs). These include studies in advanced solid tumors, prostate cancer, and uterine cancer. The company has positioned ADCs as a strategic pillar, and the depth of these data will be scrutinized for any glimmer of broad platform potential.

All this lands in a shortened trading week. US markets are closed Monday for Memorial Day, so regular trade resumes Tuesday. The stock ended Friday at €79.50, down roughly 15% over the past month and now uncomfortably close to its 52-week low of €72.50.

The ASCO readouts are more than a scientific milestone — they are a verdict on BioNTech’s transition from vaccine windfall to oncology contender. If the clinical data impress, the market may revalue the pipeline. If they disappoint, the narrative will snap back to the shrinking vaccine revenue and the high cash burn rate. Either way, Saturday’s results will set the tone for the weeks ahead.